Capecitabine and docetaxel combination for the treatment of breast cancer.
The management of breast cancer depends on the tumor and patient's characteristics. Anthracycline-based regimens have been proven to decrease the risk of relapse and prolong survival time in breast cancer. Taxanes have been incorporated not only into metastatic breast cancer but also into adjuvant regimens. Capecitabine, an oral fluoropyrimidine carbamate, has good single-agent activity and, together with docetaxel, demonstrated preclinical synergy and a survival benefit in metastatic breast cancer. Recent analyses show that capecitabine/docetaxel dosing flexibility for managing side effects does not compromise efficacy, and define this combination regimen as an important treatment option for its efficacy, tolerability and cost-effectiveness.
Morishita
Mariko
M
Imperial College Healthcare NHS Trust, Fulham Palace Road, London W68RF, UK. Robert.Leonard@imperial.nhs.uk
Leonard
Robert C
RC
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000191:economics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000523:psychology; D000069287:Capecitabine; D003362:Cost-Benefit Analysis; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000191:economics / Q000494:pharmacology; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000191:economics / Q000494:pharmacology; D006801:Humans; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000191:economics / Q000494:pharmacology*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D000068878:Trastuzumab; D005472:Fluorouracil